Understanding Who Owns US Pharma and Its Complex Landscape
•
5 min read
In 2022, over $25 billion in biopharmaceutical exports were from majority foreign-owned firms operating in the United States, highlighting the significant role international investment plays in the industry. This multifaceted financial landscape reveals that answering the question of who owns US pharma is far from straightforward, involving a mix of institutional, public, foreign, and venture capital ownership.
